Pancreatic cancer is one of the most aggressive and lethal malignancies, with median survival less than one year and fewer than five percent of patients alive five years after diagnosis. Today, the disease is the fourth leading cause of US cancer-related deaths and is predicted to move up to second by 2020 and rank first by 2025. The American Cancer Society estimates that in 2016, 53,000 people will be diagnosed with pancreatic cancer, and nearly 42,000 will die of the disease. Read the full story & the medicine behind it.CME Credit Form
The highly skilled physicians of IU Health Physicians are featured in Advanced Praxis case studies exhibiting the latest clinical trends in medicine.Subscribe to Advanced Praxis Newsletter
Pediatric cardiomyopathies are clinically heterogeneous heart muscle disorders (Table 1 see page 4) that cause systolic or diastolic dysfunction and are associated with significant morbidity and mortality. Among affected children, up to 40 percent progress to transplantation or die within five years of diagnosis. Read the full story & the medicine behind it.CME Credit Form
AAA is a degenerative process occurring between the diaphragm and the aortic bifurcation that results in a segmental, full-thickness dilatation of the abdominal aorta exceeding the normal vessel diameter by 50 percent (i.e., ≥3.0 cm). AAAs, approximately 85 percent of which are infrarenal, are usually asymptomatic until they rupture, an often fatal event with a mortality of 85 to 90 percent. Of those patients who reach the hospital, only 50 to 70 percent survive. Read the full story & the medicine behind it.
Osteosarcomas can develop in any bone but have a predilection for the metaphyseal regions of the long bones of the extremities. The femur is the most common site for osteosarcoma formation, accounting for 42 percent of all cases, three-quarters of which are located in the distal femur (Table 1). Read the full story & the medicine behind it.
ATC is a rare form of undifferentiated cancer that accounts for less than two percent of all thyroid cancers but has a disproportionately high mortality rate of 33 to 50 percent. Patients are usually in their sixth or seventh decade of life at presentation, have an average median survival of five months, and fewer than 20 percent are alive one year after diagnosis. Read the full story & the medicine behind it.